Financial Performance - The company's operating revenue for the first half of 2024 reached CNY 1,660,604,867.40, an increase of 7.10% compared to CNY 1,550,527,752.71 in the same period last year[14]. - Net profit attributable to shareholders increased significantly to CNY 393,331,967.75, up 281.93% from CNY 102,986,596.23 year-on-year[14]. - The net profit after deducting non-recurring gains and losses was CNY 362,115,052.10, a substantial increase of 313.74% compared to a loss of CNY 169,421,763.57 in the previous year[14]. - Basic earnings per share rose to CNY 0.4187, reflecting a year-on-year increase of 281.97% from CNY 0.1096[15]. - The weighted average return on net assets increased to 5.08%, up 3.64 percentage points from 1.44% in the previous year[15]. - The total assets of the company at the end of the reporting period were CNY 13,036,822,724.14, representing a 4.58% increase from CNY 12,465,874,627.30 at the end of the previous year[14]. - The net cash flow from operating activities was negative at CNY -211,292,963.43, a decline of 14.96% compared to CNY -183,801,002.30 in the same period last year[14]. Market Position and Strategy - The company attributed the increase in net profit to improved market share in traditional Chinese medicine products and reduced overall expenses during the reporting period[16]. - The Chinese traditional medicine industry is expected to reach a market size of 510 billion yuan by 2024, reflecting strong growth potential[19]. - The company ranks among the top 100 pharmaceutical companies in China, showcasing its strong brand influence and market competitiveness[21]. - The company has successfully participated in multiple procurement projects, enhancing its market share and brand impact[21]. - The company is focusing on innovation-driven development strategies, emphasizing new drug research and product innovation[22]. - The company aims to enhance its overall competitiveness and risk resistance through the integration and collaboration of the traditional Chinese medicine industry chain[22]. - The traditional Chinese medicine industry is characterized by weak cyclicality, with stable demand largely unaffected by macroeconomic fluctuations[20]. - The company is responding to national policies supporting traditional Chinese medicine, which are expected to further boost market demand[21]. Research and Development - The company is actively optimizing its research and development strategy to strengthen its product innovation capabilities[21]. - The company anticipates continued growth in the traditional Chinese medicine market due to increasing health awareness among residents and ongoing government support[21]. - The company is advancing the research and development of a new traditional Chinese medicine, having completed pharmacological and toxicological studies and received clinical trial approval[26]. - The company has a diverse R&D portfolio, including 1 innovative traditional Chinese medicine project, 3 hospital preparation registration projects, and 39 generic drug projects, emphasizing a balanced approach to traditional and chemical medicine development[62]. - The company has one innovative traditional Chinese medicine (TCM) drug in development, focusing on digestive metabolism, which has received clinical trial approval and is currently undergoing Phase II clinical trials[63]. - In the chemical drug sector, the company is developing ZBD1006, a second-generation FGFR inhibitor, which has completed 9 dose groups in Phase I clinical trials, and HZB0071, a first-in-class AKT inhibitor, showing promising potential for cancer treatment[64]. Production and Operations - The company operates 19 production workshops across three bases, with 41 production lines capable of producing various dosage forms[29]. - The company is focusing on cost control and quality management to adapt to centralized procurement policies in the pharmaceutical industry[25]. - The company has established a comprehensive product line from raw materials to biopharmaceuticals, ensuring a diverse product portfolio for clinical needs[29]. - The company implements a "sales-driven production" model, optimizing production plans based on sales forecasts and inventory levels, while also preparing for seasonal demand fluctuations[37]. Financial Management - The company has established a strategic cooperation procurement model with leading suppliers to reduce procurement costs and enhance quality, thereby improving overall competitiveness[36]. - The company has implemented a cautious business strategy in response to volatile herbal medicine prices, leading to a reduction in revenue from its herbal trading segment[33]. - The company has not proposed any profit distribution or capital reserve increase for the current period, indicating a focus on reinvestment[89]. - The company plans to repurchase and cancel 137,232 restricted stocks from two departing employees, which were granted but not yet released from restrictions[90]. Environmental Management - The company’s wastewater treatment system has a design capacity of 2,000 tons per day, utilizing an IC anaerobic tower activated sludge + A/O process[94]. - The total discharge of COD in the first half of 2024 was 16.518921 tons, with a maximum concentration of 137.631 mg/L, well below the standard of 300 mg/L[93]. - The company reported no exceedances in pollutant discharge during the reporting period[93]. - The company has established a dedicated environmental management organization and appointed a full-time environmental protection officer[99]. - The company’s environmental protection management system includes compliance with multiple national standards for air and water quality[100]. Corporate Governance - The company has committed to not engaging in competitive activities with its subsidiaries and ensuring fair treatment in related transactions[121]. - The company has undergone several capital increases since its establishment, with the latest being a non-public offering of 92.8 million shares at CNY 13.34 per share[173]. - The company confirms its financial statements comply with the relevant accounting standards and accurately reflect its financial position as of June 30, 2024[180]. - The company has a continuous operating capability for at least 12 months from the reporting date, with no significant issues affecting this capability[178].

证券代码：603567 证券简称：珍宝岛 公告编号：临 2024-054 黑龙江珍宝岛药业股份有限公司 关于收到药品上市申请不予批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 黑龙江珍宝岛药业股份有限公司（以下简称"公司"）在收到国家药品监督 管理局对公司与印度 Biological E. Limited 公司合作的注射用达托霉素颁发的 《药品上市申请不予批准通知书》后，随即提出了行政复议。近日，公司收到国 家药品监督管理局颁发的《行政复议决定书》对该品种做出的行政复议，维持了 原不予批准的决定。现就相关情况公告如下： 一、药品的基本情况 达托霉素（Daptomycin）属于环脂肽类抗生素，是一种超级抗生素产品，用 于治疗复杂性皮肤及软组织感染（cSSSI）、金黄色葡萄球菌血流感染（菌血症） 以及伴发的右侧感染性心内膜炎（RIE）。达托霉素与细菌细胞膜结合，并引起 1 细胞膜电位的快速去极化。细胞膜电位的这种缺失抑制 DNA、RNA 和蛋白质的合 成，最终导致细菌细胞死亡。 注射用达托霉素国内 1 家原研 1 ...

证券代码：603567 证券简称：珍宝岛 公告编号：临 2023-056 黑龙江珍宝岛药业股份有限公司 第五届监事会第十一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 黑龙江珍宝岛药业股份有限公司（以下简称"公司"）第五届监事会第十一 次会议于 2024 年 8 月 26 日以现场方式在公司 4 号会议室召开。会议通知已于 2024年8月15日以电子邮件方式送达至全体监事。本次会议应到参会监事3名， 实际参会监事 3 名，会议由公司监事会主席兰培宝先生主持。会议的召集和召开 符合《中华人民共和国公司法》和《公司章程》等有关规定。会议审议并通过以 下议案： （1）公司《2024 年半年度报告》全文及摘要的编制和审议程序符合法律、 法规及《公司章程》等相关规定； （2）公司《2024 年半年度报告》的内容和格式符合中国证监会和上海证券 交易所的相关规定； （3）在公司监事会提出本意见前，未发现参与半年度报告编制和审议的人 员有违反保密规定的行为。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 二、审 ...

证券代码：603567 证券简称：珍宝岛 公告编号：临 2024-055 黑龙江珍宝岛药业股份有限公司 第五届董事会第十三次会议决议公告 本议案已经审计委员会事前认可并审议通过。 具体内容详见公司同日在上海证券交易所网站 www.sse.com.cn 披露的《黑 龙江珍宝岛药业股份有限公司 2024 年半年度报告》全文及摘要。 二、审议并通过了《黑龙江珍宝岛药业股份有限公司关于 2024 年半年度募 集资金存放与实际使用情况的专项报告》 表决结果：同意 5 票，反对 0 票，弃权 0 票。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 黑龙江珍宝岛药业股份有限公司（以下简称"公司"）第五届董事会第十三 次会议于 2024 年 8 月 26 日以现场结合通讯方式在公司 3 号会议室召开。会议通 知已于 2024 年 8 月 15 日以电子邮件方式送达至全体董事。本次会议应参会董事 5 名，实际参会董事 5 名，会议由公司董事长方同华先生主持。会议的召集和召 开符合《中华人民共和国公司法》和《公司章程》等有关规定。会议审议并通过 ...

证券代码：603567 证券简称：珍宝岛 公告编号：临 2024-057 黑龙江珍宝岛药业股份有限公司 关于 2024 年半年度募集资金存放与实际使用情况的 专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 经中国证券监督管理委员会出具的《关于核准黑龙江珍宝岛药业股份有限 公司非公开发行股票的批复》（证监许可[2021]338 号）核准，黑龙江珍宝岛药 业股份有限公司（以下简称"公司"或"珍宝岛"）非公开发行人民币普通股 （A 股）92,803,592 股，发行价格为 13.34 元/股，募集资金总额为人民币 1,237,999,917.28 元,扣除本次发行费用人民币 20,759,785.06 元（不含税）且 不包括人民币普通股（A 股）发行申购资金于冻结期间产生的利息收入后，募 集资金净额为人民币 1,217,240,132.22 元，上述募集资金已于 2021 年 10 月 22 日全部到位，中准会计师事务所（特殊普通合伙）对本次非公开发行股票募集 资金到位情况进行了验证，并出具《验资报告 ...

证券代码：603567 证券简称：珍宝岛 公告编号：2024-053 黑龙江珍宝岛药业股份有限公司 2024 年第二次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 112 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 516,667,671 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 54.8580 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由董事会召集，公司董事长方同华先生主持。本次会议以现场 和网络投票相结合的方式对股东大会通知中列明的事项进行了投票表决，表决方 式符合《公司法》及《公司章程》的规定。 (五) 公司董事、监事和董事会秘书的出席情况 二、 议案审议情况 (一) 非累 ...

北京市兰台律师事务所 关于黑龙江珍宝岛药业股份有限公司 2024 年第二次临时股东大会的 法 律 意 见 书 兰台意（2024）第 3204 号 地址：北京市朝阳区曙光西里甲 1 号第三置业大厦 B 座 29 层 电话：（8610）52287799 传真：（8610）58220039 网址：www.lantai.cn 3.在本法律意见书中，本所律师根据《股东大会规则》的要求，仅就本次股 东大会的召集和召开程序、召集人和出席人员资格、表决程序、表决结果等事项 发表法律意见，不对本次股东大会提案的内容以及提案中所涉及的事实和数据的 真实性、准确性等事项发表意见。 4.本法律意见书仅供公司评价本次股东大会之目的而使用，未经本所事先书 面同意，不得用于其他任何目的或用途。本所同意将本法律意见书作为公司本次 股东大会公告材料，随其他需公告的信息一起向公众披露。 法律意见书 北京市兰台律师事务所 关于黑龙江珍宝岛药业股份有限公司 2024 年第二次临时股东大会的 法 律 意 见 书 兰台意（2024）第 3204 号 致：黑龙江珍宝岛药业股份有限公司 北京市兰台律师事务所（以下简称"本所"）接受黑龙江珍宝岛药业股份有 限 ...

2024.08.23 黑龙江珍宝岛药业股份有限公司 2024 年第二次临时股东大会 会 议 资 料 1 目录 | 2024 | 年第二次临时股东大会会议须知 3 | | --- | --- | | 2024 | 年第二次临时股东大会会议议程 4 | | 议案 | 1：黑龙江珍宝岛药业股份有限公司关于公司回购注销部分激励对象已获授 | | 但尚未解除限售的限制性股票的议案 5 | | | 议案 | 2：黑龙江珍宝岛药业股份有限公司关于减少注册资本暨修订《公司章程》 | | 的议案 8 | | 2 黑龙江珍宝岛药业股份有限公司 2024 年第二次临时股东大会会议须知 为维护全体股东的合法权益，确保股东大会的正常秩序和议事效 率，根据《公司法》、《上市公司股东大会规则》、《上海证券交易 所上市公司自律监管指引第1号——规范运作》及《公司章程》等相 关规定，特制定本次股东大会须知如下： 一、会议按照法律、法规、有关规定和《公司章程》的规定进行， 参会人员应自觉维护会议秩序。 二、股东参加股东大会，依法享有发言权、质询权、表决权等权 利，并应认真履行法定义务，不得侵犯其他股东的合法权益。 三、参会股东或股东代表应在20 ...

二、控股股东可交换公司债券本次换股价格调整情况 根据《黑龙江创达集团有限公司 2023 年面向专业投资者非公开发行可交换 公司债券（第二期）募集说明书》的约定，"在本期可交债发行期满 12 个月后， 当标的股票在任意连续 15 个交易日的收盘价低于当期换股价格，本期可交债的 换股价格自动向下修正。修正后的换股价格为当期换股价格的 90%。" 截至 2024 年 6 月 28 日，"23 创 02EB"发行完成已满 12 个月。2024 年 7 月 24 日至 2024 年 8 月 13 日，标的股票出现了在换股期内已连续 15 个交易日的收 盘价低于当期换股价格的情形，已触发可交换公司债券换股价格向下修正条件。 为保障"23 创 02EB"债券持有人利益，创达集团决定自 2024 年 8 月 16 日起"23 创 02EB"的换股价格将从 14.67 元/股向下修正为 13.20 元/股。本次换股价格 下修后，创达集团本期可交债质押专户中预备用于交换的股票数量仍满足本期可 交债全部换股所需的股票数量。 公司将密切关注本期可交债的进展情况，并根据有关规定履行持续信息披露 义务，敬请广大投资者注意投资风险。 特此 ...

Financial Performance - Operating revenue for the reporting period was CNY 1,550,527,752.71, down 37.44% year-on-year [3]. - Net profit attributable to shareholders was CNY 102,986,596.23, a decline of 56.94% compared to the same period last year [3]. - The net cash flow from operating activities was negative CNY 183,801,002.30, a significant decrease of 759.62% year-on-year [3]. - Basic earnings per share were CNY 0.1096, down 56.83% from CNY 0.2539 in the previous year [3]. - The weighted average return on net assets decreased by 1.90 percentage points to 1.44% [3]. Assets and Shareholder Information - Total assets at the end of the reporting period were CNY 11,375,015,131.28, a decrease of 2.59% compared to the end of the previous year [2]. - The total number of shareholders at the end of the reporting period was 20,114 [4]. - The largest shareholder, Heilongjiang Chuangda Group Co., Ltd., holds 51.38% of the shares, amounting to 483,985,300 shares [4]. Operational Situation - The company did not report any significant changes in its operational situation during the reporting period [6]. - There were no new strategies or major events reported that would significantly impact the company's future operations [6].